First Month of GDUFA II Sees Large Spike in Generic CRLs

Drug Industry Daily
In the first month of the GDUFA II program, the FDA sent 325 complete response letters to generics manufacturers — far more than the high of 190 seen in August of the fiscal year before.

To View This Article:


Subscribe To Drug Industry Daily